RWD in post-approval monitoring of Camzyos™ for people with cardiomyopathy: healthcare technology company PicnicHealth announces collaboration with Bristol Myers Squibb

Healthcare technology company PicnicHealth announces a new engagement with Bristol Myers Squibb to leverage RWD from their DISCOVER-HCM registry of people with symptomatic obstructive hypertrophic cardiomyopathy in post-approval study of Camzyos™ treatment.

---

Healthcare technology company PicnicHealth has announced a new engagement with Bristol Myers Squibb (BMS) to facilitate generation of RWE from the DISCOVER-HCM registry of people being treated for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) with the recently approved Camzyos™.

Camzyos™, developed by BMS, constitutes a step-change in treatment of cardiomyopathy. It is a cardiac myosin inhibitor and directly addresses the underlying pathology of oHCM. Camzyos™ was approved by the FDA in April 2022 to improve functional capacity and symptoms in adults with New York Heart Association class II–III symptomatic oHCM.

BMS set up their DISCOVER-HCM consented registry of 1,500 patients with symptomatic oHCM receiving Camzyos™ or other treatments in order to evaluate the comparative safety, treatment patterns, short- and long-term outcomes, and healthcare resource utilization of people in the US with symptomatic oHCM treated in the real-world clinical setting.

PicnicHealth is a healthcare technology company that partners directly with patients to build deep real-world datasets. To the new collaboration, RWD specialists PicnicHealth will bring their state-of-the-art machine learning combined with expert medical data curation to complement DISCOVER-HCM. The engagement is designed to help BMS unlock new insights about long-term, real-world patient experiences within the DISCOVER-HCM registry.

For patients participating in the DISCOVER-HCM registry who choose to opt-in to the PicnicHealth data research project, PicnicHealth’s technology will be used to collect their historical and prospective medical information, including emergency room visits, hospitalizations, care at other clinics and other medical events, to supplement the registry data. Capturing and organizing these data in clinically rich, de-identified medical records will improve investigators’ understanding of participants’ complete medical journeys, including medication use, comorbidities, and past medical procedures.

‍“It can be difficult to get a complete picture of patients’ experiences with the healthcare system, even for patients enrolled in clinical trials,” said Noga Leviner, CEO and co-founder at PicnicHealth. “Consented real-world patient data from PicnicHealth can be helpful in post-approval studies because it gives the study sponsor ongoing access to patients’ complete medical records helping them better understand patient experiences and outcomes.”

This data research project has the potential to demonstrate how using technology-powered, patient-centric data collection from real-world, routine medical care can improve how long-term, post-marketing studies are performed and enable a better understanding of the risks and benefits of treatments in the real world.